Literature DB >> 18844713

What every physician should know about polycystic ovary syndrome.

Robert L Rosenfield1.   

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine cause of hirsutism, acne, and pattern alopecia. It is a heterogeneous syndrome of hyperandrogenic anovulation that is typically due to intrinsic ovarian dysfunction, which is often aggravated by insulin-resistant hyperinsulinemia with its risks of diabetes mellitus and metabolic syndrome and their complications. Because there are many pitfalls to androgen assays, evaluation for hyperandrogenemia is suggested in women with moderate or severe hirsutism or hirsutism equivalents, menstrual irregularity, acanthosis nigricans, or intractable obesity. An endocrinologic work-up is necessary to rule out other hyperandrogenic disorders that require specific therapy (e.g., virilizing tumors, nonclassic congenital adrenal hyperplasia, hyperprolactinemia, and Cushing's syndrome). Ultrasonography helps in the differential diagnosis and may demonstrate the polycystic ovaries that have recently been vetted as an alternative to oligo-anovulation as a diagnostic criterion. Management of PCOS is determined by symptomatology. For those women not desiring pregnancy, the most common therapies are oral contraceptive pills, antiandrogens (contraindicated in the absence of adequate contraception), and insulin-lowering treatments (which have little effect on hirsutism).

Entities:  

Mesh:

Year:  2008        PMID: 18844713     DOI: 10.1111/j.1529-8019.2008.00217.x

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  7 in total

1.  Interventional studies for polycystic ovarian syndrome in children and adolescents.

Authors:  Patricia Myriam Vuguin
Journal:  Ped Health       Date:  2010-02

2.  Association Between Adult Acne and Dietary Behaviors: Findings From the NutriNet-Santé Prospective Cohort Study.

Authors:  Laetitia Penso; Mathilde Touvier; Mélanie Deschasaux; Fabien Szabo de Edelenyi; Serge Hercberg; Khaled Ezzedine; Emilie Sbidian
Journal:  JAMA Dermatol       Date:  2020-08-01       Impact factor: 10.282

3.  Oral contraceptive use among women in the military and the general U.S. population.

Authors:  Lindsey Enewold; Louise A Brinton; Katherine A McGlynn; Shelia H Zahm; John F Potter; Kangmin Zhu
Journal:  J Womens Health (Larchmt)       Date:  2010-05       Impact factor: 2.681

4.  How do Individuals with Complete Androgen Insensitivity Syndrome, Mayer-Rokitansky-Küster-Hauser Syndrome or Polycystic Ovary Syndrome Experience Contact to Other Affected Persons?

Authors:  K Krupp; M Fliegner; F Brunner; S Brucker; K Rall; H Richter-Appelt
Journal:  Geburtshilfe Frauenheilkd       Date:  2012-11       Impact factor: 2.915

5.  Congenital adrenal hyperplasia.

Authors:  Cleo Dessinioti; Andreas Katsambas
Journal:  Dermatoendocrinol       Date:  2009-03-01

6.  The efficacy of oral isotretinoin versus cyproterone compound in female patients with acne and the triad of cutaneous hyperandrogenism: A randomized clinical trial.

Authors:  Gita Faghihi; Kioumars Jamshidi; Nabet Tajmirriahi; Bahareh Abtahi-Naeini; Mohamadali Nilforoshzadeh; Mohamadreza Radan; Sayed Mohsen Hosseini
Journal:  Adv Biomed Res       Date:  2014-12-31

Review 7.  Metabolomics in Central Sensitivity Syndromes.

Authors:  Joseph S Miller; Luis Rodriguez-Saona; Kevin V Hackshaw
Journal:  Metabolites       Date:  2020-04-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.